Reported Earlier, AstraZeneca Says Tagrisso Reduces Risk Of Death By 48% Versus Placebo In Overall Stage IB-IIIA Trial Population, With 79% Alive At Eight Years Versus 64%
Longest survival data ever reported in a global Phase III trial in this settingNew data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages
AstraZeneca's lung cancer medicine Tagrisso helped people live longer in a big study. When you see a company report strong survival results, that hints the medicine is working well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.